Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma

Brachytherapy

Volumn 2, Issue 4, 2003, Pages 215-222

  Ellis, Rodney J ^a,c,e   Vertocnik, Amy ^b   Sodee, Bruce ^c   Zhou, Hang ^c   Kim, Edward ^c   Young, Ben ^b   Fu, Pingfu ^c   Colussi, Valdir ^c   Spirnak, John P ^d   Dinchman, Kurt H ^d   Resnick, Martin I ^c  

^a AULTMAN HOSPITAL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d METROHEALTH MEDICAL CENTER   (United States)

^e Stark Radiation Oncology   (United States)

Author keywords

Brachytherapy; EBRT; ProstaScint; Prostate; Radioimmunoguided

Indexed keywords

LEAD;

ADULT; AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; PALLADIUM; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION; RADIOISOTOPES; RADIOTHERAPY, CONFORMAL; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 12144290199     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2003.12.002     Document Type: Article

References (21)

1. American Cancer Society. Cancer facts and figures-2003. 2003;American Cancer Society, Atlanta, GA.
2. Stock R.G., Stone N.N. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol. 13:1997;454-460.
3. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
4. Wright G.L., Haley C., Beckett M.L., et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1:1995;18-28.
5. Silver D.A., Pellicer I., Fair W.R., et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 3:1997;81-85.
6. ®: Semiquantitative correlation with prostate biopsy results. Prostate. 37:1998;140-148.
7. Ellis R.J., Kim E.Y., Conant R., et al. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys. 49:2001;1281-1286.
8. Ellis R.J., Sodee D.B., Spirnak J.P., et al. Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 48:2000;483-487.
9. ASTRO Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
10. Kestin L.L., Vicini F.A., Martinez A.A. Practical application of biochemical failure definitions: What to do and when to do it. Int J Radiat Oncol Biol Phys. 53:2002;304-315.
11. Merrick G.S., Butler W.M., Galbreath R.W., et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys. 51:2001;41-48.
12. Hanlon A.L., Diratzouian H., Hanks G.E. Post treatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 53:2002;297-303.
13. Grado G.L., Larson T.R., Balch C.S., et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys. 42:1998;289-298.
14. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma. Cancer. 97:2003;979-983.
15. Lee L., Stock R.G., Stone N.N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 52:2002;444-452.
16. Lederman G.S., Cavanagh W., Albert P.S., et al. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys. 49:2001;1297-1303.
17. Blasko J.C., Grimm P.D., Sylsvester J.E. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate adenocarcinoma. Radiother Oncol. 57:2000;273-278.
18. Zeitlin S.I., Sherman J., Raboy A., et al. High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol. 160:1998;91-96.
19. Critz F.A. A standard definition of disease freedom is needed for prostate cancer: Undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol. 167:2002;1310-1313.
20. Ragde H., Elgamal A.A., Snow P., et al. Ten-year disease free survival after transperineal sonography-guided Iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 83:1998;989-1001.
21. Singh A., Zelefsky M.J., Raben A., et al. Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer. Int J Cancer. 90:2000;275-280.